Profile data is unavailable for this security.
About the company
KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drug therapies for diseases with significant unmet need. Its product candidate is sebetralstat, an inhibitor of plasma kallikrein being developed for hereditary angioedema (HAE). Sebetralstat is designed to offer people living with HAE a medication that can be taken as a discreet oral dose to readily treat HAE attacks on-demand, including at the earliest signs before the attack fully develops. Sebetralstat works by targeting the kallikrein-kinin system (KKS) cascade, selectively inhibiting plasma kallikrein and its uncontrolled activity that drives HAE attacks. The Company is also designing an oral Factor XIIa inhibitor for HAE prophylaxis, positioning KalVista to address the full spectrum of HAE disease management. Factor XIIa inhibitor program is developed to address other therapeutic areas, including inflammation and thrombosis.
- Revenue in USD (TTM)0.00
- Net income in USD-141.77m
- Incorporated2004
- Employees150.00
- LocationKalvista Pharmaceuticals Inc55 Cambridge Pkwy Ste 901ECAMBRIDGE 02142-1234United StatesUSA
- Phone+1 (857) 999-0075
- Fax+1 (302) 531-3150
- Websitehttps://www.kalvista.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Foghorn Therapeutics Inc. | 25.52m | -91.22m | 429.18m | 116.00 | -- | -- | -- | 16.82 | -1.91 | -1.91 | 0.5133 | -0.5088 | 0.0821 | -- | -- | 219,956.90 | -29.34 | -31.35 | -35.57 | -35.69 | -- | -- | -357.53 | -777.33 | -- | -- | -- | -- | 77.63 | -- | 9.60 | -- | -4.50 | -- |
| ACELYRIN Inc | 0.00 | -264.41m | 432.17m | 130.00 | -- | 0.8192 | -- | -- | -2.68 | -2.68 | 0.00 | 5.29 | 0.00 | -- | -- | 0.00 | -37.27 | -- | -41.69 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -489.21 | -- | -- | -- |
| Allogene Therapeutics Inc | 43.00k | -283.43m | 442.41m | 232.00 | -- | 0.9532 | -- | 10,288.56 | -1.53 | -1.53 | 0.0002 | 2.21 | 0.00007 | -- | -- | 185.34 | -43.56 | -28.46 | -46.04 | -30.21 | -- | -- | -659,137.20 | -1,123.44 | -- | -- | 0.00 | -- | -39.10 | -- | 3.86 | -- | -14.06 | -- |
| Taysha Gene Therapies Inc | 9.92m | -22.77m | 446.78m | 52.00 | -- | 5.03 | -- | 45.06 | -0.0625 | -0.0625 | 0.0421 | 0.4333 | 0.0527 | -- | -- | 190,673.10 | -12.11 | -- | -27.40 | -- | -- | -- | -229.67 | -- | -- | -- | 0.328 | -- | 517.55 | -- | 32.80 | -- | -- | -- |
| Omeros Corp | 0.00 | -185.38m | 447.93m | 198.00 | -- | -- | -- | -- | -3.14 | -2.30 | 0.00 | -2.66 | 0.00 | -- | -- | 0.00 | -45.98 | -55.51 | -61.42 | -70.10 | -- | -- | -- | -- | -- | -6.07 | 1.59 | -- | -- | -- | 3.91 | -- | -5.56 | -- |
| Aura Biosciences Inc | 0.00 | -83.22m | 447.94m | 88.00 | -- | 2.57 | -- | -- | -1.73 | -1.73 | 0.00 | 3.51 | 0.00 | -- | -- | 0.00 | -43.22 | -- | -46.30 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.03 | -- | -- | -- |
| Olema Pharmaceuticals Inc | 0.00 | -122.68m | 450.69m | 87.00 | -- | 2.27 | -- | -- | -2.19 | -2.19 | 0.00 | 3.47 | 0.00 | -- | -- | 0.00 | -46.92 | -30.06 | -51.51 | -31.40 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.76 | -- | -- | -- |
| Y-mAbs Therapeutics Inc | 84.55m | -23.86m | 452.37m | 100.00 | -- | 4.89 | -- | 5.35 | -0.541 | -0.541 | 1.92 | 2.06 | 0.677 | 1.13 | 4.36 | 845,530.00 | -19.11 | -44.23 | -23.55 | -50.45 | 88.89 | -- | -28.22 | -181.13 | 3.54 | -- | 0.00 | -- | 29.96 | -- | 77.58 | -- | -- | -- |
| Regenxbio Inc | 84.33m | -238.81m | 454.82m | 344.00 | -- | 1.51 | -- | 5.39 | -5.03 | -5.03 | 1.76 | 6.09 | 0.1463 | -- | 3.27 | 245,136.60 | -41.43 | -16.75 | -51.75 | -19.08 | 54.36 | 78.27 | -283.19 | -72.06 | -- | -- | 0.00 | -- | -19.94 | -16.21 | 6.00 | -- | -5.59 | -- |
| OmniAB Inc | 20.41m | -63.02m | 454.93m | 106.00 | -- | 1.59 | -- | 22.29 | -0.6227 | -0.6227 | 0.2017 | 2.43 | 0.0564 | -- | 4.24 | 192,537.70 | -17.43 | -- | -18.43 | -- | -- | -- | -308.78 | -- | -- | -- | 0.00 | -- | -42.17 | -- | -126.65 | -- | -- | -- |
| MeiraGTx Holdings PLC | 13.93m | -88.18m | 456.93m | 389.00 | -- | 4.80 | -- | 32.80 | -1.30 | -1.30 | 0.2123 | 1.23 | 0.0492 | -- | 1.08 | 33,243.44 | -31.12 | -26.40 | -39.74 | -32.66 | -7.72 | -- | -633.05 | -420.70 | -- | -- | 0.4324 | -- | -11.95 | -- | 35.17 | -- | 12.37 | -- |
| Kalvista Pharmaceuticals Inc | 0.00 | -141.77m | 457.69m | 150.00 | -- | 2.32 | -- | -- | -3.54 | -3.54 | 0.00 | 4.01 | 0.00 | -- | -- | 0.00 | -78.65 | -40.63 | -87.52 | -43.67 | -- | -- | -- | -2,972.81 | -- | -- | 0.00 | -- | -- | -- | -36.31 | -- | -16.34 | -- |
| Arcturus Therapeutics Holdings Inc | 160.40m | -62.64m | 462.38m | 180.00 | -- | 1.77 | -- | 2.88 | -2.33 | -2.33 | 5.95 | 9.67 | 0.3873 | -- | 4.69 | 891,105.60 | -15.13 | -19.66 | -18.67 | -24.90 | -- | -- | -39.05 | -77.55 | -- | -- | 0.00 | -- | -19.03 | 60.31 | -417.95 | -- | 14.44 | -- |
| Korro Bio Inc | 0.00 | -101.60m | 470.71m | 95.00 | -- | 2.63 | -- | -- | -17.04 | -17.04 | 0.00 | 19.28 | 0.00 | -- | -- | 0.00 | -70.10 | -31.55 | -76.20 | -36.48 | -- | -- | -- | -365.87 | -- | -104.93 | 0.00 | -- | -- | -- | 0.5001 | -- | 78.21 | -- |
| Celcuity Inc | 0.00 | -93.97m | 471.39m | 55.00 | -- | 3.16 | -- | -- | -2.61 | -2.61 | 0.00 | 4.03 | 0.00 | -- | -- | 0.00 | -45.24 | -37.32 | -49.93 | -39.16 | -- | -- | -- | -- | -- | -- | 0.393 | -- | -- | -- | -57.99 | -- | -31.12 | -- |
| Terns Pharmaceuticals Inc | 0.00 | -88.07m | 481.92m | 66.00 | -- | 1.33 | -- | -- | -1.18 | -1.18 | 0.00 | 4.29 | 0.00 | -- | -- | 0.00 | -27.10 | -41.34 | -28.12 | -45.70 | -- | -- | -- | -31,010.30 | -- | -- | 0.00 | -- | -- | -- | -49.49 | -- | -26.60 | -- |
Data as of Nov 22 2024. Currency figures normalised to Kalvista Pharmaceuticals Inc's reporting currency: US Dollar USD
59.25%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Tang Capital Management LLCas of 30 Sep 2024 | 4.32m | 10.00% |
| Suvretta Capital Management LLCas of 30 Sep 2024 | 4.21m | 9.75% |
| Vestal Point Capital LPas of 30 Sep 2024 | 4.00m | 9.26% |
| Capital Research & Management Co. (World Investors)as of 30 Sep 2024 | 3.37m | 7.81% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 2.80m | 6.48% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 2.07m | 4.80% |
| Adage Capital Management LPas of 30 Sep 2024 | 1.42m | 3.29% |
| Great Point Partners LLCas of 30 Sep 2024 | 1.30m | 3.01% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 1.27m | 2.94% |
| Emerald Advisers LLCas of 30 Sep 2024 | 835.99k | 1.93% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
